Abstract: Described herein are compositions and combinations comprising an antibody that binds thymic stromal lymphopoietin (TSLP) and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.

Abstract: Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), an antibody or antigen binding fragment thereof that binds OX40L, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Abstract: Described herein are compositions and combinations comprising an antibody that binds OX40L and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.

Abstract: The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via a dual cleavable linker and an anchoring moiety. The extracellular vesicles can be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

Abstract: The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via a cleavable linker comprising a cell penetrating peptide and an anchoring moiety. The extracellular vesicles can be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

Abstract: Provided herein are methods of preventing or treating a tumor in a subject in need thereof comprising administering to the subject a dose of an IL-12 polypeptide, wherein the amount of the IL-12 polypeptide in the dose is about 0.1 ?g to about 30 ?g.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing high-quality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing high-quality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to methods of loading an EV with a payload. In some aspects, the payload and the EV are mixed at a specific loading condition (e.g., at the disclosed salt concentrations, loading temperature, loading duration, payload feed concentration, and/or EV feed concentration), such that the amount of the payload that is associated with the exterior surface of the EV is increased. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

Abstract: The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, e.g., infectious diseases.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing highquality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to methods for preparing extracellular vesicles (EVs). In particular, the methods provided herein comprise contacting a sample, which comprises EVs and one or more impurities, with a depth filter, wherein the depth filter is selected from a LA media grade depth filter, a SP media grade depth filter, or both. In some aspects, the methods further comprise one or more chromatography steps. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via an optimized linker and an anchoring moiety, which may be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

Abstract: The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, which can be rapidly modified to comprise an antigen of interest, and the uses of such EVs as vaccines for the treatment of wide range of diseases or disorders. Also provided herein are methods for preparing and manufacturing such EVs for use as vaccines.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing high-quality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing high quality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: Provided herein are methods of preparing EVs, e.g., exosomes, associated with or encapsulated various cyclic dinucleotides, including STING agonists. Also provided herein are methods of loading EVs, e.g., exosomes, with various cyclic dinucleotides, including STING agonists.

Abstract: The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing highquality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.

Abstract: The present disclosure relates to high-throughput screening methods for identifying one or more chromatography operational parameters (e.g., binding parameters) and/or reagents for purifying EVs (e.g., exosomes) from a sample using chromatography. Also disclosed herein are methods for improving one or more aspects of EV (e.g., exosome) purification, e.g., improving EV yield, increasing EV ligand density, and/or reducing impurity recovery.

Abstract: The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an AAV and a scaffold protein. In some aspects, the AAV is in the lumen of the extracellular vesicle. In some aspects, the AAV is associated with the luminal surface of the extracellular vesicle. In some aspects, the AAV is associated with the exterior surface of the extracellular vesicle. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.